FORMATION OF GLYCINE CONJUGATE AND (-)-(R)-ENANTIOMER FROM (+)-(S)-2-PHENYLPROPIONIC ACID SUGGESTING THE FORMATION OF THE COA THIOESTER INTERMEDIATE OF (+)-(S)-ENANTIOMER IN DOGS

被引:44
作者
TANAKA, Y [1 ]
SHIMOMURA, Y [1 ]
HIROTA, T [1 ]
NOZAKI, A [1 ]
EBATA, M [1 ]
TAKASAKI, W [1 ]
SHIGEHARA, E [1 ]
HAYASHI, R [1 ]
CALDWELL, J [1 ]
机构
[1] UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT PHARMACOL & TOXICOL,LONDON SW7 2AZ,ENGLAND
关键词
ARYLPROPIONIC ACID; 2-PHENYLPROPIONIC ACID; GLYCINE CONJUGATION; STEREOSELECTIVITY; CHIRAL INVERSION; REVERSE CHIRAL INVERSION; GLYCINE N-ACYL TRANSFERASE; DOG HEPATOCYTES; CHIRAL HPLC;
D O I
10.1002/chir.530040603
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
It has been proposed that the chiral inversion of the 2-arylpropionic acids is due to the stereospecific formation of the (-)-R-profenyl-CoA thioesters which are putative intermediates in the inversion. Accordingly, amino acid conjugation, for which the CoA thioesters are obligate intermediates, should be restricted to those optical forms which give rise to the (-)-R-profenyl-CoA, i.e., the racemates and the (-)-(R)-isomers. We have examined this problem in dogs with respect to 2-phenylpropionic acid(2-PPA). Regardless of the optical configuration of 2-phenylpropionic acid administered, the glycine conjugate was the major urinary metabolite and this was shown to be exclusively the (+)-(S)-enantiomer by chiral HPLC. Both (-)-(R)- and (+)-(S)-2-phenylpropionic acid were present in plasma after the administration of either antipode, and further evidence of the chiral inversion of both enantiomers was provided by the presence of some 25% of the opposite enantiomer in the free 2-phenylpropionic acid and its glucuronide excreted in urine after administration of (-)-(R)- and (+)-(S)-2-phenylpropionic acid. The (+)-(S)-enantiomer underwent chiral inversion to the (-)-(R)-antipode when incubated with dog hepatocytes. These data suggests that both enantiomers of 2-phenylpropionic acid are substrates for canine hepatic acyl CoA ligase(s) and thus undergo chiral inversion, but that the CoA thioester of only (+)-(S)-2-phenylpropionic acid is a substrate for the glycine N-acyl transferase. These studies are presently being extended to the structure and species specificity of the reverse inversion and amino acid conjugation of profen NSAIDs.
引用
收藏
页码:342 / 348
页数:7
相关论文
共 16 条
[1]   PHARMACOKINETICS OF IBUPROFEN ENANTIOMERS IN DOGS [J].
BECK, WS ;
GEISSLINGER, G ;
ENGLER, H ;
BRUNE, K .
CHIRALITY, 1991, 3 (03) :165-169
[2]   THE METABOLIC CHIRAL INVERSION AND DISPOSITIONAL ENANTIOSELECTIVITY OF THE 2-ARYLPROPIONIC ACIDS AND THEIR BIOLOGICAL CONSEQUENCES [J].
CALDWELL, J ;
HUTT, AJ ;
FOURNELGIGLEUX, S .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (01) :105-114
[3]  
CALDWELL J, 1978, CONJUGATION REACTION, P111
[4]   METABOLIC STEREOISOMERIC INVERSION OF IBUPROFEN IN MAMMALS [J].
CHEN, CS ;
SHIEH, WR ;
LU, PH ;
HARRIMAN, S ;
CHEN, CY .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1078 (03) :411-417
[5]   METABOLISM OF ARYLACETIC ACIDS .2. FATE OF [HYDRATROPIC-C-14] ACID AND ITS VARIATION WITH SPECIES [J].
DIXON, PAF ;
CALDWELL, J ;
SMITH, RL .
XENOBIOTICA, 1977, 7 (11) :707-715
[6]   THE METABOLIC CHIRAL INVERSION OF 2-PHENYLPROPIONIC ACID IN RAT, MOUSE AND RABBIT [J].
FOURNEL, S ;
CALDWELL, J .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (23) :4153-4159
[7]   THE IMPORTANCE OF STEREOCHEMISTRY IN THE CLINICAL PHARMACOKINETICS OF THE 2-ARYLPROPIONIC ACID NON-STEROIDAL ANTI-INFLAMMATORY DRUGS [J].
HUTT, AJ ;
CALDWELL, J .
CLINICAL PHARMACOKINETICS, 1984, 9 (04) :371-373
[8]   THE METABOLIC CHIRAL INVERSION OF 2-ARYLPROPIONIC ACIDS - A NOVEL ROUTE WITH PHARMACOLOGICAL CONSEQUENCES [J].
HUTT, AJ ;
CALDWELL, J .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1983, 35 (11) :693-704
[9]   APPLICATION OF A RADIAL COMPRESSION COLUMN TO THE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC SEPARATION OF THE ENANTIOMERS OF SOME 2-ARYLPROPIONIC ACIDS AS THEIR DIASTEREOISOMERIC S-(-)-1-(NAPHTHEN-1-YL)ETHYLAMIDES [J].
HUTT, AJ ;
FOURNEL, S ;
CALDWELL, J .
JOURNAL OF CHROMATOGRAPHY, 1986, 378 (02) :409-418
[10]  
IWAKAWA S, 1991, DRUG METAB DISPOS, V19, P717